Literature DB >> 3091346

Pseudomonas aeruginosa susceptibility in a university hospital: recognition and treatment.

J C Rotschafer, L R Shikuma.   

Abstract

Pseudomonas aeruginosa continues to be a leading cause of nosocomial bacteremia and other serious, often life-threatening infections. The incidence of P. aeruginosa infection appears to be increasing. The resilience of Pseudomonas in the hospital environment, its endogenous virulence factors, and its current level of resistance to antimicrobials make it a formidable pathogen, particularly in a compromised host. Despite the availability of several effective antipseudomonal antibiotics, infections caused by this pathogen are still associated with significant morbidity and mortality. Early recognition and prompt intervention with appropriate antimicrobial agents are vital to successful management. Combination therapy with an aminoglycoside and an extended-spectrum penicillin or cephalosporin is recommended in the initial management of suspected or documented P. aeruginosa infections.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3091346     DOI: 10.1177/106002808602000714

Source DB:  PubMed          Journal:  Drug Intell Clin Pharm        ISSN: 0012-6578


  3 in total

1.  Therapy of pseudomonal infections.

Authors:  A Kumar
Journal:  Indian J Pediatr       Date:  1987 Jul-Aug       Impact factor: 1.967

2.  DsbM, a novel disulfide oxidoreductase affects aminoglycoside resistance in Pseudomonas aeruginosa by OxyR-regulated response.

Authors:  Xuehan Wang; Mingxuan Li; Liwei Liu; Rui Mou; Xiuming Zhang; Yanling Bai; Haijin Xu; Mingqiang Qiao
Journal:  J Microbiol       Date:  2012-12-30       Impact factor: 3.422

3.  Synergistic antibacterial and anti-biofilm activities of resveratrol and polymyxin B against multidrug-resistant Pseudomonas aeruginosa.

Authors:  Lin Qi; Rongxin Liang; Jingjing Duan; Songze Song; Yunjun Pan; Hui Liu; Mingan Zhu; Lian Li
Journal:  J Antibiot (Tokyo)       Date:  2022-08-23       Impact factor: 3.424

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.